Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Jensyn Acquisition Corp. Announces Pricing of Initial Public Offering
-
Unique Fabricating, Inc. Reports Fourth Quarter and Full Year 2015 Results
-
Chardan Capital Markets Downgrades DigitalGlobe (DGI) to Neutral
-
Chardan Capital Markets Upgrades The KEYW Holding Corporation (KEYW) to Buy
-
Amarantus Announces $3M Capital Infusion
-
Chardan Capital Markets Downgrades Mesoblast Limited (MESO) to Neutral
-
Chardan Capital Markets Starts BioTime, Inc. (BTX) at Buy
-
UPDATE: Chardan Capital Markets Upgrades Regeneron Pharma (REGN) to Neutral
-
AveXis (AVXS) IPO Opens Down 10%
-
AveXis Announces Pricing of Initial Public Offering
-
Notable Analyst Rating Changes 2/10: (TDG) (DF) (SCTY) Upgraded; (XL) (KNX) (AINV) Downgraded
-
UPDATE: Chardan Capital Markets Starts iRobot Corporation (IRBT) at Buy
-
22nd Century Group (XXII) Enters $5.5M Common Stock, Warrants Registered Direct Offering
-
22nd Century Group Announces $5.5 Million Registered Direct Offering
-
Chardan Capital Markets Downgrades Profire Energy (PFIE) to Neutral
-
Giggles N' Hugs, Inc. (GIGL) CEO Discusses 2016 Growth Strategies in Second QualityStocks Interview
-
Notable Analyst Rating Changes 1/25: (RSYS) (HD) (JBHT) Upgraded; (REGN) (TWTR) (WFM) Downgraded
-
Chardan Capital Markets Upgrades Voyager Therapeutics (VYGR) to Neutral
-
Chardan Capital Markets Downgrades Regeneron Pharma (REGN) to Sell
-
Inventergy Global (INVT) Announces $2.5M Conv. Preferred, Warrants Private Placement
-
Inventergy Announces Private Placement of $2.5 Million
-
AveXis (AVXS) Files $115M IPO
-
Chardan Closes Biotie/Axovant (AXON) Preference Following Acorda Deal; Reaffirms at 'Sell'
-
Chardan Capital Markets acts as Sole Placement Agent for PierianDx in its $9.25 Million Series A Financing
-
Chardan Capital Markets Starts Ituran Location & Control (ITRN) at Buy
-
Ambarella (AMBA): New Products Should Help it Break Free From the GoPro Curse - Chardan Capital Markets
-
Perion (PERI) Undervalued Relative to Mobile Ad Potential; Chardan Reaffirms at 'Buy'
-
PlacementTracker Publishes 2015 PIPE Market League Tables
-
Chardan Capital Markets Starts IDI, Inc. (IDI) at Buy, PT of $12.50
-
BTCS Provides Corporate Update and 2016 Outlook
-
Chardan Capital Cautious on Esperion (ESPR) Partnership Ahead of Phase 3 Data
-
Joseph Gonnella Retires as CEO for Enerpulse Technologies
-
Premier Biomedical Announces $1.6mil Financing – Consolidates Funding Needs Through 2016
-
Orbital Tracking Corp. Completes $1.1 Million Private Placement
-
Chardan Capital Lifts PT on REGENXBIO (RGNX) to $35 Amid New FDA RPD Designation for RGX-111
-
Chardan Capital Trims PT on StemCells (STEM) to $1 Amid Capital Preservation Plans
-
Notable Analyst Rating Changes 12/23: (EEFT) (OKE) (DLPH) Upgraded; (MU) (BBBY) (SCS) Downgraded
-
Chardan Capital Markets Starts Eyegate Pharmaceuticals (EYEG) at Buy
-
Chardan Capital Initiates Coverage on Spark Therapeutics (ONCE) at Neutral
-
TiGenix (TIG) Files for U.S. IPO; Plans to List on Nasdaq Global Market
-
TiGenix files Registration Statement for proposed initial public offering in the United States
-
TiGenix files Registration Statement for proposed initial public offering in the United States
-
Streetinsider.com's Hot Lunchtime Reads 12/21: (AAPL) (TSLA) (LBIO) (PAA) (MSFT)
-
Chardan Capital Reaffirms Lion Biotech (LBIO) at 'Buy'; TILs Expected to be Tested in Variety of Cancer Settings
-
Chardan Capital Markets Starts Skyworks Solutions (SWKS) at Buy
-
Pre-Open Stock Movers 12/14: (AKBA) (DEST) (TSL) Higher; (ATRA) (NWL) (GPRO) Lower (more...)
-
Chardan Capital Lifts PT on Ophthotech (OPHT) to $200; Notes Recent Upgrades to Fovista
-
Chardan Capital Markets Starts Voyager Therapeutics (VYGR) at Sell
-
UPDATE: Chardan Capital Markets Starts CalAmp Corp. (CAMP) at Buy
-
Chardan Capital No Longer Expects Underperformance from Orexigen Therapeutics (OREX)

